FDA inspection
Aurolife Pharma, LLC: FDA inspection ending Dec 7, 2021
FDA inspection 1158258 · Official Action Indicated (OAI) · Dayton, NJ
Key facts
| Inspection ID | 1158258 |
|---|---|
| Firm | Aurolife Pharma, LLC |
| FEI number | 3005796917 |
| Address | 2400 US Highway 130 |
| City | Dayton |
| State | NJ |
| ZIP | 08810 |
| Country | United States |
| Fiscal year | 2022 |
| Inspection end date | Dec 7, 2021 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data